FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

William Copalu

Research Profile

Chemicals & Drugs

Activities & Behaviors

Concepts & Ideas

Disorders

Anatomy

Phenomena

Protein Binding

Living Beings

Young Adult

Co-author Network

Publications

TOP 3
L A Devriese; G Edwards; A Jenner; S Marchetti; M Mergui-Roelvink; F Peng; Larisa Reyderman; Jos H Beijnen; William Copalu; J Wanders; J H M Schellens
Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole.
Lot A Devriese; Geoff Edwards; Alwin D R Huitema; Kenneth Law; Serena Marchetti; Fuping Peng; Larisa Reyderman; Jos H Beijnen; William Copalu; Emile E Voest; Jantien Wanders; Petronella Els O Witteveen; Jan H M Schellens
Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin.
Nathalie Guffon; Yves Kibleur; C Tissen; William Copalu; Jörg Breitkreutz
Developing a new formulation of sodium phenylbutyrate.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of William Copalu (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: L A Devriese; G Edwards; A Jenner; S Marchetti; M Mergui-Roelvink; F Peng; Larisa Reyderman; Jos H Beijnen; William Copalu; J Wanders; J H M Schellens
Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole.
Investigational new drugs 2013;31(2):381-9.
2013: Lot A Devriese; Geoff Edwards; Alwin D R Huitema; Kenneth Law; Serena Marchetti; Fuping Peng; Larisa Reyderman; Jos H Beijnen; William Copalu; Emile E Voest; Jantien Wanders; Petronella Els O Witteveen; Jan H M Schellens
Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin.
British journal of clinical pharmacology 2013;75(2):507-15.
2012: Nathalie Guffon; Yves Kibleur; C Tissen; William Copalu; Jörg Breitkreutz
Developing a new formulation of sodium phenylbutyrate.
Archives of disease in childhood 2012;97(12):1081-5.
2012: D S Boss; William Copalu; Jos H Beijnen; H Glen; M Keesen; A Mazur; R Morrison; J P O'Brien; J H M Schellens; B Tait; J Wanders; T R J Evans
A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours.
British journal of cancer 2012;106(10):1598-604.
2011: A C Dubbelman; Hilde Rosing; Bas Thijssen; L Lucas; William Copalu; J Wanders; J H M Schellens; Jos H Beijnen
Validation of high-performance liquid chromatography-tandem mass spectrometry assays for the quantification of eribulin (E7389) in various biological matrices.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2011;879(15-16):1149-55.
2010: Anthe S Zandvliet; Mats O Karlsson; Jan H M Schellens; William Copalu; Jos H Beijnen; Alwin D R Huitema
Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents.
Investigational new drugs 2010;28(1):61-75.
2009: Anthe S Zandvliet; Jan H M Schellens; William Copalu; Jos H Beijnen; Alwin D R Huitema
Covariate-based dose individualization of the cytotoxic drug indisulam to reduce the risk of severe myelosuppression.
Journal of pharmacokinetics and pharmacodynamics 2009;36(1):39-62.
2008: Anthe S Zandvliet; Wandena S Siegel-Lakhai; Jos H Beijnen; William Copalu; M-C Etienne-Grimaldi; G Milano; J H M Schellens; Alwin D R Huitema
PK/PD model of indisulam and capecitabine: interaction causes excessive myelosuppression.
Clinical pharmacology and therapeutics 2008;83(6):829-39.
2007: Anthe S Zandvliet; Alwin D R Huitema; William Copalu; Yasuhide Yamada; Tomohide Tamura; Jos H Beijnen; Jan H M Schellens
CYP2C9 and CYP2C19 polymorphic forms are related to increased indisulam exposure and higher risk of severe hematologic toxicity.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(10):2970-6.
2006: Anthe S Zandvliet; Jan H M Schellens; William Copalu; Jos H Beijnen; Alwin D R Huitema
A semi-physiological population pharmacokinetic model describing the non-linear disposition of indisulam.
Journal of pharmacokinetics and pharmacodynamics 2006;33(5):543-70.
2006: Anthe S Zandvliet; William Copalu; Jan H M Schellens; Jos H Beijnen; Alwin D R Huitema
Saturable binding of indisulam to plasma proteins and distribution to human erythrocytes.
Drug metabolism and disposition: the biological fate of chemicals 2006;34(6):1041-6.